STAVUDINE

US Previously Marketed

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C10H12N2O4
Molecular Weight	224.2133
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=CN([C@@H]2O[C@H](CO)C=C2)C(=O)NC1=O

InChI

InChIKey=XNKLLVCARDGLGL-JGVFFNPUSA-N

InChI=1S/C10H12N2O4/c1-6-4-12(10(15)11-9(6)14)8-3-2-7(5-13)16-8/h2-4,7-8,13H,5H2,1H3,(H,11,14,15)/t7-,8+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C10H12N2O4
Molecular Weight	224.2133
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.drugbank.ca/drugs/DB00649
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020412s029,020413s020lbl.pdf

Stavudine is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Stavudine is phosphorylated to active metabolites that compete for incorporation into viral DNA. They inhibit the HIV reverse transcriptase enzyme competitively and act as a chain terminator of DNA synthesis. The lack of a 3'-OH group in the incorporated nucleoside analogue prevents the formation of the 5' to 3' phosphodiester linkage essential for DNA chain elongation, and therefore, the viral DNA growth is terminated. Stavudine inhibits the activity of HIV-1 reverse transcriptase (RT) both by competing with the natural substrate dGTP and by its incorporation into viral DNA. Stavudine is used for the treatment of human immunovirus (HIV) infections. Stavudine is sold under the brand name Zerit among others.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Human immunodeficiency virus 1 34 Target ID: CHEMBL378 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020412s029,020413s020lbl.pdf	Inhibitor 8504		1.9 µM [IC50]
Human immunodeficiency virus type 1 reverse transcriptase 70 Target ID: CHEMBL247 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020412s029,020413s020lbl.pdf	Inhibitor 8504		0.0083 µM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
HIV-1 infection 156 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020412s029,020413s020lbl.pdf	Primary		Approved 8583	Zerit Approved Use ZERIT (stavudine), in combination with other antiretroviral agents, is indicated for the treatment of HIV-1 infection Launch Date 1994

C_max

Value	Dose	Co-administered	Analyte	Population
228 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21453_Zerit_lbl.pdf	100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		STAVUDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
536 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020412s041,020413s033lbl.pdf	40 mg 2 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		STAVUDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
1966 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21453_Zerit_lbl.pdf	100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		STAVUDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
2568 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020412s041,020413s033lbl.pdf	40 mg 2 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		STAVUDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
100% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21453_Zerit_lbl.pdf	100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		STAVUDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
100% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020412s041,020413s033lbl.pdf	40 mg 2 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		STAVUDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15249567/	unhealthy, 36.5 Health Status: unhealthy Age Group: 36.5 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/15249567/	Other AEs: Abdominal pain, Asthenia... Other AEs: Abdominal pain (19%) Asthenia (18%) Headache (25%) Diarrhea (34%) Dyspepsia (12%) Nausea (24%) Vomiting (12%) Lipodystrophy (6%) Arthralgia (6%) Myalgia (4%) Abnormal dreams (19%) Depressive disorders (13%) Dizziness (26%) Insomnia (22%) Neuropathy (13%) Paresthesia (12%) Cough increased (9%) Rhinitis (11%) Rash (35%) Skin discoloration (<1%) Sources: https://pubmed.ncbi.nlm.nih.gov/15249567/
40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20412S017.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20412S017.pdf	Other AEs: Headache, Diarrhea... Other AEs: Headache (54 patients) Diarrhea (50 patients) Neuropathy peripheral (52 patients) Rash (40 patients) Nausea and vomiting (39 patients) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20412S017.pdf
40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20412S017.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20412S017.pdf	Other AEs: Nausea, Diarrhea... Other AEs: Nausea (43 patients) Diarrhea (34 patients) Headache (25 patients) Rash (18 patients) Vomiting (18 patients) Neuropathy peripheral (8 patients) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20412S017.pdf
40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20412S017.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20412S017.pdf	Other AEs: Nausea, Diarrhea... Other AEs: Nausea (53 patients) Diarrhea (45 patients) Headache (46 patients) Rash (30 patients) Vomiting (30 patients) Neuropathy peripheral (21 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20412S017.pdf

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946 inhibitor 2252	substrate 1193 inhibitor 2438	substrate 1388 inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2C8 1057 CYP2B6 926 CYP1A2 2153 CYP2A6 879 CYP2C19 2057 CYP2E1 1060 BSEP 550 MRP2 499 MRP3 246 MRP4 290	CYP1A2 1197 CYP2C19 1119 BCRP 697 P-gp 2052	P-gp 301

Drug as perpetrator

Target	Modality	Activity
CYP1A2 2333	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzU2IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDk5MSJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2A6 911	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDk5MSJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNjIyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDk5MSJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzk3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDk5MSJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyODkiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMOTkxIn19	no [IC50 >10 uM]
CYP2E1 1146	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDk5MSJ9fQ%3D%3D	no [IC50 >10 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMOTkxIn19	no [IC50 >10 uM]
BSEP 554	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
MRP2 625	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
MRP3 326	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
MRP4 345	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
CYP2B6 1160	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/17101742/	unlikely
CYP2C8 1117	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/15601807/	weak
P-gp 1932	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/18310046/	weak

Drug as victim

Target	Modality	Activity
CYP1A2 1197	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021453_S000_Zerit_BioPharmR.pdf#page=11 Page: 11.0	no
CYP2C19 1119	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021453_S000_Zerit_BioPharmR.pdf#page=11 Page: 11.0	no
CYP2C9 1193	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021453_S000_Zerit_BioPharmR.pdf#page=11 Page: 11.0	no
CYP2D6 1388	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021453_S000_Zerit_BioPharmR.pdf#page=11 Page: 11.0	no
CYP3A4 1946	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021453_S000_Zerit_BioPharmR.pdf#page=11 Page: 11.0	no
BCRP 697	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/17202245/	yes
P-gp 2052	substrate 4014 Sources: https://www.sciencedirect.com/science/article/pii/S0024320510004005	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMOTkxIn19

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:63581	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:63581
ChemicalBook	CB4450928	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB4450928
eMolecules	536927	https://www.emolecules.com/cgi-bin/more?vid=536927
eMolecules	739264	https://www.emolecules.com/cgi-bin/more?vid=739264
MolPort	MolPort-002-507-283	https://www.molport.com/shop/molecule-link/MolPort-002-507-283
ZINC	ZINC000000137884	http://zinc15.docking.org/substances/ZINC000000137884

PubMed

Title	Date	PubMed
Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5.	2001-09-14	11454872
Mismatched double-stranded RNA (polyI-polyC(12)U) is synergistic with multiple anti-HIV drugs and is active against drug-sensitive and drug-resistant HIV-1 in vitro.	2001-09	11448730
Susceptibility of human T cell leukemia virus type 1 to reverse-transcriptase inhibitors: evidence for resistance to lamivudine.	2001-08-15	11471110
Eruptive cheilitis: a new adverse effect in reactive HIV-positive patients subjected to high activity antiretroviral therapy (HAART). Presentation of six clinical cases.	2001-08-08	11488127
Metformin in an HIV-infected patient with protease inhibitor-induced diabetic ketoacidosis.	2001-08-04	11485138
Genotypic correlates of a virologic response to stavudine after zidovudine monotherapy.	2001-08-01	11468426
Value of patient self-report and plasma human immunodeficiency virus protease inhibitor level as markers of adherence to antiretroviral therapy: relationship to virologic response.	2001-08-01	11438909
Antiviral drugs: current state of the art.	2001-08	11418355
Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression.	2001-07-27	11504959
Warning for pregnant women on HIV therapy.	2001-07-19	11458554
Stavudine versus zidovudine and the development of lipodystrophy.	2001-07-01	11464142
Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion.	2001-07	11486172
Predictors of protease inhibitor-associated adverse events.	2001-07	11478584
In vivo pharmacokinetics and metabolism of anti-human immunodeficiency virus agent D4T-5'-[p-bromophenyl methoxyalaninyl phosphate] (SAMPIDINE) in mice.	2001-07	11408371
Gynaecomastia in a male patient during stavudine and didanosine treatment for HIV infection.	2001-07	11394987
Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis.	2001-06-29	11442229
Differential incorporation and removal of antiviral deoxynucleotides by human DNA polymerase gamma.	2001-06-29	11319228
Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).	2001-06-15	11372025
Selection by AZT and rapid replacement in the absence of drugs of HIV type 1 resistant to multiple nucleoside analogs.	2001-06-10	11429122
Adherence over 48 weeks in an antiretroviral clinical trial: variable within patients, affected by toxicities and independently predictive of virological response.	2001-06	11491422
Severe lactic acidosis and thiamine administration in an HIV-infected patient on HAART.	2001-06	11368826
Lactic acid levels in children perinatally treated with antiretroviral agents to prevent HIV transmission.	2001-05-25	11399997
Persistence of zidovudine-resistance mutations in HIV-1 isolates from patients removed from zidovudine therapy for at least 3 years and switched to a stavudine-containing regimen.	2001-05-25	11399996
New developments in anti-HIV chemotherapy.	2001-05-12	11347962
Fatal portal hypertension, liver failure, and mitochondrial dysfunction after HIV-1 nucleoside analogue-induced hepatitis and lactic acidaemia.	2001-05-05	11356442
Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection.	2001-05-04	11399957
HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health.	2001-05-04	11399956
Lipodystrophy in HIV-infected children is associated with high viral load and low CD4+ -lymphocyte count and CD4+ -lymphocyte percentage at baseline and use of protease inhibitors and stavudine.	2001-05-01	11404517
An integrated system to study multiply substituted human immunodeficiency virus type 1 reverse transcriptase.	2001-05-01	11319828
Choosing which nuke to use first.	2001-05	11392690
Effect of stavudine on mitochondrial genome and fatty acid oxidation in lean and obese mice.	2001-05	11303038
R211K and L214F do not invariably confer high level phenotypic resistance to thymidine analogs in zidovudine-naive patients with M184V.	2001-04-15	11391177
Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy.	2001-04-15	11304769
Long-term safety and efficacy of nevirapine, stavudine and lamivudine in a real-world setting.	2001-04-13	11371699
Differing reverse transcriptase mutation patterns in individuals experiencing viral rebound on first-line regimens with stavudine/didanosine and stavudine/lamivudine.	2001-04-13	11371696
Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy.	2001-04-13	11371686
Determination of serum levels of thirteen human immunodeficiency virus-suppressing drugs by high-performance liquid chromatography.	2001-04-13	11355843
Treatment of hyperlipidemia in HIV-infected patients.	2001-04-01	11296612
[A rare etiology of hepatic steatosis associated with lactic acidosis: the toxicity of antiviral nucleoside analogues].	2001-04	11373588
An open-label randomized trial to evaluate different therapeutic strategies of combination therapy in HIV-1 infection: design, rationale, and methods of the initio trial.	2001-04	11306154
ACTG (AIDS Clinical Trials Group) 384: a strategy trial comparing consecutive treatments for HIV-1.	2001-04	11306153
Gynecomastia associated with highly active antiretroviral therapy.	2001-04	11302408
Amino acid deletion at codon 67 and Thr-to-Gly change at codon 69 of human immunodeficiency virus type 1 reverse transcriptase confer novel drug resistance profiles.	2001-04	11264389
Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs.	2001-03-30	11316999
Peripheral neuropathy and antiretroviral drugs.	2001-03	11293802
Large hepatic mitochondrial DNA deletions associated with L-lactic acidosis and highly active antiretroviral therapy.	2001-02-16	11273225
Bristol-Myers warns of AIDS drugs' use.	2001-02	11279879
Gene mutations identified.	2001-01	11265651
Tolerability of postexposure antiretroviral prophylaxis for occupational exposures to HIV.	2001	11480491
Macrocytosis in patients on stavudine.	2001	11303821

Patents

Sample Use Guides

In Vivo Use Guide

Adults: The recommended dose based on body weight is as follows: 40 mg twice daily for patients ≥60 kg. 30 mg twice daily for patients <60 kg.

Route of Administration: Oral

In Vitro Use Guide

The concentration of Stavudine necessary to inhibit HIV-1 replication by 50% (EC50) ranged from 0.009 to 4 uM

Substance Class	Chemical Created by `admin` on `Wed Apr 02 07:04:54 GMT 2025` Edited by `admin` on `Wed Apr 02 07:04:54 GMT 2025`
Record UNII	BO9LE4QFZF
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SANILVUDINE

Preferred Name

English

STAVUDINE

Official Name

English

STAVUDINE [WHO-IP]

Common Name

English

STAVUDINE [MI]

Common Name

English

STAVUDINE [USAN]

Common Name

English

STAVUDINE (D4T) [VANDF]

Common Name

English

Stavudine [WHO-DD]

Common Name

English

ZERIT

Brand Name

English

D-4T

Code

English

STAVUDINE [USP MONOGRAPH]

Common Name

English

NSC-163661

Code

English

stavudine [INN]

Common Name

English

STAVUDINE [EP MONOGRAPH]

Common Name

English

THYMIDINE, 2',3'-DIDEHYDRO-3'-DEOXY-

Systematic Name

English

NSC-759897

Code

English

STAVUDINUM [WHO-IP LATIN]

Common Name

English

STAVUDINE [EMA EPAR]

Common Name

English

STAVUDINE [HSDB]

Common Name

English

ZIDOVUDINE IMPURITY A [WHO-IP]

Common Name

English

1-((2R,5S)-5-(HYDROXYMETHYL)-2,5-DIHYDROFURAN-2-YL)-5-METHYLPYRIMIDINE-2,4(1H,3H)-DIONE

Common Name

English

STAVUDINE [EP IMPURITY]

Common Name

English

STAVUDINE (DT4) [VANDF]

Common Name

English

STAVUDINE [ORANGE BOOK]

Common Name

English

STAVUDINE [MART.]

Common Name

English

1-(2,3-DIDEOXY-.BETA.-D-GLYCERO-PENT-2-ENOFURANOSYL)THYMINE

Common Name

English

ZIDOVUDINE IMPURITY A [EP IMPURITY]

Common Name

English

STAVUDINE [USP-RS]

Common Name

English

SANILVUDINE [JAN]

Common Name

English

D4T

Code

English

Classification Tree Code System Code

NDF-RT

N0000175462